Latest Insider Transactions at Laboratory Corp Of America Holdings (LH)
This section provides a real-time view of insider transactions for Laboratory Corp Of America Holdings (LH). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of LABORATORY CORP OF AMERICA HOLDINGS to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of LABORATORY CORP OF AMERICA HOLDINGS's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 24
2024
|
Kerrii B Anderson Director |
SELL
Open market or private sale
|
Direct |
1,000
-6.79%
|
$230,000
$230.0 P/Share
|
|
Aug 19
2024
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,000
-35.28%
|
$454,000
$227.05 P/Share
|
|
Aug 15
2024
|
Glenn A Eisenberg Chief Financial Officer, EVP |
SELL
Open market or private sale
|
Direct |
15,000
-11.91%
|
$3,345,000
$223.61 P/Share
|
|
Aug 08
2024
|
Kerrii B Anderson Director |
SELL
Open market or private sale
|
Direct |
586
-3.83%
|
$131,850
$225.0 P/Share
|
|
Aug 07
2024
|
Kerrii B Anderson Director |
SELL
Open market or private sale
|
Direct |
414
-2.63%
|
$93,150
$225.0 P/Share
|
|
Aug 05
2024
|
Lance Berberian EVP, CIO & CTO |
SELL
Open market or private sale
|
Direct |
12,093
-23.12%
|
$2,769,297
$229.36 P/Share
|
|
Jun 06
2024
|
Paul Rothman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
717
+50.0%
|
-
|
|
May 14
2024
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,000
-13.5%
|
$420,000
$210.83 P/Share
|
|
May 02
2024
|
Kerrii B Anderson Director |
SELL
Open market or private sale
|
Direct |
250
-1.57%
|
$50,000
$200.1 P/Share
|
|
Apr 30
2024
|
Kerrii B Anderson Director |
SELL
Open market or private sale
|
Direct |
250
-1.54%
|
$51,000
$204.13 P/Share
|
|
Apr 30
2024
|
Glenn A Eisenberg Chief Financial Officer, EVP |
SELL
Payment of exercise price or tax liability
|
Direct |
4,496
-8.85%
|
$903,696
$201.37 P/Share
|
|
Apr 30
2024
|
Glenn A Eisenberg Chief Financial Officer, EVP |
BUY
Exercise of conversion of derivative security
|
Direct |
10,229
+16.77%
|
-
|
|
Apr 29
2024
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,439
-53.89%
|
$497,556
$204.33 P/Share
|
|
Apr 15
2024
|
Glenn A Eisenberg Chief Financial Officer, EVP |
SELL
Payment of exercise price or tax liability
|
Direct |
4,496
-9.98%
|
$912,688
$203.32 P/Share
|
|
Apr 15
2024
|
Glenn A Eisenberg Chief Financial Officer, EVP |
BUY
Exercise of conversion of derivative security
|
Direct |
10,229
+18.5%
|
-
|
|
Apr 01
2024
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Open market or private sale
|
Direct |
6,477
-56.26%
|
$1,405,509
$217.29 P/Share
|
|
Apr 01
2024
|
Megan D. Bailey EVP, Chief Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
69
-13.66%
|
$14,904
$216.35 P/Share
|
|
Apr 01
2024
|
Megan D. Bailey EVP, Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
205
+28.87%
|
-
|
|
Apr 01
2024
|
Amy B. Summy EVP, Chief Marketing Officer |
SELL
Open market or private sale
|
Direct |
3,500
-46.82%
|
$759,500
$217.29 P/Share
|
|
Mar 28
2024
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,553
-31.75%
|
$767,448
$216.74 P/Share
|
|
Mar 27
2024
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,605
-18.89%
|
$562,680
$216.57 P/Share
|
|
Mar 27
2024
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,158
+30.86%
|
-
|
|
Mar 27
2024
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,061
-15.36%
|
$1,093,176
$216.57 P/Share
|
|
Mar 27
2024
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
11,556
+25.97%
|
-
|
|
Mar 27
2024
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,079
-30.61%
|
$1,097,064
$216.57 P/Share
|
|
Mar 27
2024
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
11,556
+41.05%
|
-
|
|
Mar 27
2024
|
Adam H Schechter President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
31,799
-25.35%
|
$6,868,584
$216.57 P/Share
|
|
Mar 27
2024
|
Adam H Schechter President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
72,435
+36.61%
|
-
|
|
Mar 27
2024
|
Jonathan P. Di Vincenzo EVP, Pres, Central Labs & Intl |
SELL
Payment of exercise price or tax liability
|
Direct |
952
-14.85%
|
$205,632
$216.57 P/Share
|
|
Mar 27
2024
|
Jonathan P. Di Vincenzo EVP, Pres, Central Labs & Intl |
BUY
Exercise of conversion of derivative security
|
Direct |
3,012
+31.96%
|
-
|
|
Mar 27
2024
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
894
-16.49%
|
$193,104
$216.57 P/Share
|
|
Mar 27
2024
|
Peter J Wilkinson SVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,079
+36.23%
|
-
|
|
Mar 27
2024
|
Amy B. Summy EVP, Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,162
-22.43%
|
$466,992
$216.57 P/Share
|
|
Mar 27
2024
|
Amy B. Summy EVP, Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,778
+37.48%
|
-
|
|
Mar 27
2024
|
Glenn A Eisenberg Chief Financial Officer, EVP |
SELL
Payment of exercise price or tax liability
|
Direct |
8,805
-20.18%
|
$1,901,880
$216.57 P/Share
|
|
Mar 27
2024
|
Glenn A Eisenberg Chief Financial Officer, EVP |
BUY
Exercise of conversion of derivative security
|
Direct |
20,033
+31.47%
|
-
|
|
Mar 27
2024
|
Lance Berberian EVP, CIO & CTO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,299
-10.54%
|
$712,584
$216.57 P/Share
|
|
Mar 27
2024
|
Lance Berberian EVP, CIO & CTO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,697
+19.73%
|
-
|
|
Mar 07
2024
|
Amy B. Summy EVP, Chief Marketing Officer |
SELL
Open market or private sale
|
Direct |
227
-5.56%
|
$49,486
$218.45 P/Share
|
|
Mar 07
2024
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Open market or private sale
|
Direct |
5,048
-50.06%
|
$1,100,464
$218.45 P/Share
|
|
Mar 07
2024
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,119
+17.36%
|
$247,923
$117.09 P/Share
|
|
Feb 21
2024
|
Glenn A Eisenberg Chief Financial Officer, EVP |
SELL
Open market or private sale
|
Direct |
34,504
-19.67%
|
$7,452,864
$216.64 P/Share
|
|
Feb 21
2024
|
Glenn A Eisenberg Chief Financial Officer, EVP |
BUY
Exercise of conversion of derivative security
|
Direct |
14,054
+19.48%
|
$2,290,802
$163.63 P/Share
|
|
Feb 21
2024
|
Jonathan P. Di Vincenzo EVP, Pres, Central Labs & Intl |
SELL
Open market or private sale
|
Direct |
500
-12.82%
|
$107,500
$215.49 P/Share
|
|
Feb 13
2024
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
237
-3.01%
|
$53,562
$226.45 P/Share
|
|
Feb 12
2024
|
Jonathan P. Di Vincenzo EVP, Pres, Central Labs & Intl |
SELL
Payment of exercise price or tax liability
|
Direct |
59
-1.49%
|
$13,393
$227.45 P/Share
|
|
Feb 12
2024
|
Glenn A Eisenberg Chief Financial Officer, EVP |
SELL
Payment of exercise price or tax liability
|
Direct |
215
-0.49%
|
$48,805
$227.45 P/Share
|
|
Feb 12
2024
|
Adam H Schechter President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,231
-2.27%
|
$279,437
$227.45 P/Share
|
|
Feb 12
2024
|
Amy B. Summy EVP, Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
66
-1.59%
|
$14,982
$227.45 P/Share
|
|
Feb 12
2024
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
126
-1.56%
|
$28,602
$227.45 P/Share
|